Regulatory News:

DEINOVE (Paris:ALDEI), a biotech company developing innovative processes for producing biofuels and bio-based chemicals from non-food biomass with its Deinococcus bacteria, announces today its provisional financial calendar for 2016.*

March 24, 2016     Publication of 2015 Annual Results
May 10, 2016     Annual Shareholders Meeting, in Paris
September 29, 2016     Publication of 2016 First Half Financial Results

* This financial calendar is for indicative purposes only and the Company could change its publication dates should it deem necessary.

About DEINOVE

DEINOVE (Alternext Paris: ALDEI) is ushering in a new era of green chemistry by designing and developing new standards of production based on bacteria of untapped potential: the Deinococci. Taking advantage of the bacteria’s unique genetic properties and unusual robustness, DEINOVE optimizes natural fermentation and metabolic capabilities of these bacterial "micro‐factories" to produce high value‐added products from non‐food biomass. The Company’s primary markets are 2nd‐generation biofuels (DEINOL) and bio‐based chemicals (DEINOCHEM). On these markets, the Company offers its technology to industrial partners globally.
Listed on NYSE Alternext since April 2010, DEINOVE was founded by Dr. Philippe Pouletty, General Partner of TRUFFLE CAPITAL, and Pr. Miroslav Radman, of the Faculty of Medicine of Paris Descartes University. The company employs almost 50 people in its offices and laboratories located in Montpellier, France.
More information at www.deinove.com